Despite evolving guidelines and new evidence, many older adults in the United States continue to use aspirin for the primary prevention of cardiovascular disease (CVD). This persistence occurs even though the benefits of aspirin for primary prevention are increasingly questioned. Click here for article.

Only a modest portion of the U.S. population qualifies for aspirin use under the 2022 U.S. Preventive Services Task Force (USPSTF) guidelines, with about 5 million adults aged 40-59 eligible after accounting for bleeding risks.
Updated guidelines from the American College of Cardiology and the American Heart Association in 2019 advise against frequent aspirin use for primary prevention due to the lack of net benefit and increased bleeding risks.
A poll by the University of Michigan's National Poll on Healthy Aging revealed that about one in four adults aged 50 to 80 take aspirin at least three times a week, with nearly 60 percent lacking a history of heart disease.
The USPSTF now recommends against starting aspirin for primary prevention in adults aged 60 or older, highlighting the increased risk of bleeding over potential benefits.
Comments